{"transactions":[{"id":934014,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-01-21T23:10:35.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":19547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2026 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":19547,"derivative":{"exercise_price":3,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":19547},"source":{"system":"sec-edgar","filing":"0000912282-26-000087","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228226000087/form4.xml","form_type":"4"}},{"id":1119126,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-06T21:27:06.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest 100% on the one-year anniversary of the grant date.  The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy."}],"balance_after":27000,"derivative":{"exercise_price":1.09,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000912282-25-000617","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000091228225000617/form4.xml","form_type":"4"}},{"id":1306351,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-01-09T00:33:26.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":31613,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal quarterly installments over a one year-period. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy."}],"balance_after":31613,"derivative":{"exercise_price":1.88,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":31613},"source":{"system":"sec-edgar","filing":"0001415889-25-001164","document":"form4-01092025_120123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588925001164/form4-01092025_120123.xml","form_type":"4"}},{"id":1486074,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-06-08T01:04:19.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date."}],"balance_after":27000,"derivative":{"exercise_price":0.82,"exercise_date":"2025-06-05","expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001415889-24-016092","document":"form4-06082024_010616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000141588924016092/form4-06082024_010616.xml","form_type":"4"}},{"id":1811658,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-09T22:18:36.000Z","date":"2023-08-08","kind":"purchase","planned":false,"acquired":true,"shares":8000,"price":1.23,"value":9840.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001209191-23-045231","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123045231/doc4.xml","form_type":"4"}},{"id":1875870,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-26T21:49:15.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023."}],"balance_after":27000,"derivative":{"exercise_price":1.58,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-23-032677","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919123032677/doc4.xml","form_type":"4"}},{"id":2237236,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T00:41:25.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022."}],"balance_after":27000,"derivative":{"exercise_price":3.23,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-22-035671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919122035671/doc4.xml","form_type":"4"}},{"id":2544131,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-10-12T21:48:46.000Z","date":"2021-10-08","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022."}],"balance_after":84911,"derivative":{"exercise_price":17,"expiration_date":"2029-05-07","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001209191-21-060264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121060264/doc4.xml","form_type":"4"}},{"id":2544130,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T21:48:46.000Z","date":"2021-10-08","kind":"sale","acquired":false,"shares":1000,"price":88.93,"value":88930.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-060264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121060264/doc4.xml","form_type":"4"}},{"id":2544129,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-12T21:48:46.000Z","date":"2021-10-08","kind":"exercise","acquired":true,"shares":1000,"price":17,"value":17000.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001209191-21-060264","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121060264/doc4.xml","form_type":"4"}},{"id":2597130,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-08-18T21:30:22.000Z","date":"2021-08-16","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022."}],"balance_after":85911,"derivative":{"exercise_price":17,"expiration_date":"2029-05-07","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-21-052285","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121052285/doc4.xml","form_type":"4"}},{"id":2597129,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:30:22.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":48,"price":98.9,"value":4747.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-052285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121052285/doc4.xml","form_type":"4"}},{"id":2597128,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:30:22.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":423,"price":97.55,"value":41263.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $97.22 to $97.97, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":48,"source":{"system":"sec-edgar","filing":"0001209191-21-052285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121052285/doc4.xml","form_type":"4"}},{"id":2597127,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:30:22.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":1429,"price":96.51,"value":137912.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $96.12 to $97.04, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":471,"source":{"system":"sec-edgar","filing":"0001209191-21-052285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121052285/doc4.xml","form_type":"4"}},{"id":2597126,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:30:22.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":1044,"price":95.57,"value":99775.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $95.07 to $96.07, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1900,"source":{"system":"sec-edgar","filing":"0001209191-21-052285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121052285/doc4.xml","form_type":"4"}},{"id":2597125,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:30:22.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":3056,"price":94.55,"value":288944.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $94.06 to $95.06, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2944,"source":{"system":"sec-edgar","filing":"0001209191-21-052285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121052285/doc4.xml","form_type":"4"}},{"id":2597124,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:30:22.000Z","date":"2021-08-16","kind":"exercise","acquired":true,"shares":6000,"price":17,"value":102000.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-21-052285","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121052285/doc4.xml","form_type":"4"}},{"id":2651111,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T21:26:57.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":100,"price":55.73,"value":5573.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-043707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121043707/doc4.xml","form_type":"4"}},{"id":2651110,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T21:26:57.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":250,"price":55.03,"value":13757.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001209191-21-043707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121043707/doc4.xml","form_type":"4"}},{"id":2651109,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T21:26:57.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":200,"price":55.01,"value":11002.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2020."}],"balance_after":350,"source":{"system":"sec-edgar","filing":"0001209191-21-043707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121043707/doc4.xml","form_type":"4"}},{"id":2662767,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T23:27:31.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":11029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 16, 2021."}],"balance_after":11029,"derivative":{"exercise_price":50.56,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":11029},"source":{"system":"sec-edgar","filing":"0001209191-21-041714","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919121041714/doc4.xml","form_type":"4"}},{"id":3115779,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-10T00:14:47.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":11029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date."}],"balance_after":11029,"derivative":{"exercise_price":41.73,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":11029},"source":{"system":"sec-edgar","filing":"0001209191-20-035421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919120035421/doc4.xml","form_type":"4"}},{"id":3212801,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-12T20:40:25.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":550,"price":17,"value":9350.0,"ownership":{"direct":true},"balance_after":550,"source":{"system":"sec-edgar","filing":"0001209191-20-018537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919120018537/doc4.xml","form_type":"4"}},{"id":3533119,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":69041,"kind":"person","name":"McLoughlin Margaret","position":1,"cik":"0001770823","reported_name":"McLoughlin Margaret","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-05-09T21:18:27.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":91911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 1/3rd of the shares on May 8, 2020, with the remaining 2/3rd of shares vesting in equal monthly installments beginning on June 8, 2020 and ending on May 8, 2022."}],"balance_after":91911,"derivative":{"exercise_price":17,"expiration_date":"2029-05-07","underlying":"Common Stock","underlying_shares":91911},"source":{"system":"sec-edgar","filing":"0001209191-19-028537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662774/000120919119028537/doc4.xml","form_type":"4"}}]}